Physician profile
Anthony Botti
NPI 1598787640
$274,565.37
in general payments reported to CMS, 2019-2025
45 companies · $610 in 2025
The $610 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $51K · 2021: $33K · 2022: $52K · 2023: $6,676 · 2024: $800 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,480 · Food and Beverage: $2,441 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,220 · Travel and Lodging: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,480.00 |
| Food and Beverage | $2,441.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,220.00 |
| Travel and Lodging | $945.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $96,230.27 | 2019-2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $86,813.68 | 2019-2024 | |
| Dova Pharmaceuticals | $52,501.38 | 2019-2021 | |
| Sobi, INC | $26,580.95 | 2022 | |
| Alexion Pharmaceuticals, INC. | $3,452.37 | 2019-2025 | Ultomiris |
| Apellis Pharmaceuticals, INC. | $3,382.17 | 2021-2023 | Empaveli |
| Amgen INC. | $1,075.45 | 2019-2025 | Evenity, Prolia, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $592.85 | 2021-2025 | Entyvio, Vpriv |
| Daiichi Sankyo INC. | $515.28 | 2019-2022 | |
| Horizon Therapeutics Plc | $455.97 | 2019-2023 | Krystexxa |
| Gilead Sciences, INC. | $426.63 | 2019-2025 | Biktarvy |
| Pharmacyclics LLC, An Abbvie Company | $387.78 | 2019-2021 | |
| Genentech USA, INC. | $291.80 | 2019-2023 | Ocrevus |
| Lundbeck LLC | $224.76 | 2022-2025 | Vyepti |
| Janssen Biotech, INC. | $206.49 | 2019-2025 | Tremfya, Stelara |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Botti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.